Suzie J. Scales

Yahoo (United States) — United States

Medicine · Health Sciences

43h-index10.7kcitations139works20.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(37), HER2/EGFR in Cancer Research(30), Hedgehog Signaling Pathway Studies(17), Cellular transport and secretion(16), Growth Hormone and Insulin-like Growth Factors(16)

Publications139 total

Interferon-γ induces combined pyroptotic angiopathy and APOL1 expression in human kidney disease
Cell Reports·2024· 24 citedOpen Access
Apolipoprotein L1 (APOL1) renal risk variant-mediated podocyte cytotoxicity depends on African haplotype and surface expression
Scientific Reports·2024· 16 citedOpen Access
Multi-ancestry GWAS analysis identifies two novel loci associated with diabetic eye disease and highlights APOL1 as a high risk locus in patients with diabetic macular edema
PLoS Genetics·2023· 7 citedOpen Access
Supplementary Table 2 from An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
2023Open Access
Supplementary Figure 2 from An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
2023Open Access
Supplementary Figure 2 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
2023Open Access
Data from An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
2023Open Access
Supplementary Figure 1 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
2023Open Access
Supplementary Figure 2 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
2023Open Access
Supplementary Figure 2 from An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
2023Open Access
Supplementary Table 1 from An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
2023Open Access
Supplementary Figure 1 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
2023Open Access
Supplementary figures and Tables from Preclinical Efficacy of an Antibody–Drug Conjugate Targeting Mesothelin Correlates with Quantitative <sup>89</sup>Zr-ImmunoPET
2023Open Access
Supplementary Figure 1 from An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
2023Open Access
Supplementary Materials and Methods and Supplementary Figure Legends from An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
2023Open Access
Supplementary Figure 4 from An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
2023Open Access
Supplementary Figure Legends from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
2023Open Access
Supplementary Figure 4 from FcRL5 as a Target of Antibody–Drug Conjugates for the Treatment of Multiple Myeloma
2023Open Access
Supplementary Figure 3 from An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
2023Open Access
Supplementary Materials and Methods and Supplementary Figure Legends from An Antimesothelin-Monomethyl Auristatin E Conjugate with Potent Antitumor Activity in Ovarian, Pancreatic, and Mesothelioma Models
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Xiaohui Wen(13), Richard H. Scheller(10), Frédéric J. de Sauvage(9), Shang‐Fan Yu(5), Allen Ebens(4), Richard Vandlen(4), Thomas E. Kreis(4), Andrew S. Peterson(4), Gladys S. Ingle(4), Sarajane Ross(4), Jean-Philippe Stéphan(4), Susan D. Spencer(3), J. Fernando Bazán(3), Peter K. Jackson(3), J. Michael Elliott(3), Linda Rangell(3), Yu A. Chen(3), Sejal M. Patel(3), Andrew G. Polson(3), Wesley Chang(3)